You are currently viewing Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Featured content in this Issue:

  • Canada’s First Published Psilocybin Trial: Includes Patients with BDII and Personality Disorders, Employs Flexible Repeat Dosing Protocol
  • University of Maryland Joins Terran Biosciences’ Complaint Against Compass Pathways
  • Further Reading & Other Stories

PA+ Header Psychedelic Alpha

This content is for Pα+ Subscribers

This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Sign-in button

Join Button